About 11 results found for searched term "IMP2-IN-3" (0.157 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M43166 | IMP2-IN-3 | Others |
| IMP2-IN-3 is a potent IMP2 inhibitor. | ||
| M4390 | Imperatorin | NO Synthase |
| Ammidin | ||
| Imperatorin is a potent NO synthesis inhibitor with an IC50 of 9.2 μmol and a BChE inhibitor with an IC50 of 31.4 μmol. Imperatorin is a weak agonist of TRPV1 with an EC50 of 12.6±3.2 μM. | ||
| M5043 | 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine | Others |
| 4-Chloro-7H-pyrrolo[2,3-d] pyrimidine is an important pharmaceutical intermediate, which is widely used in the synthesis of many pharmaceutical intermediates at home and abroad. Including CP690550, CGP76030 and so on, 4-Chloro-7H-pyrrolo[2,3-d] pyrimidine was the scaffold for many commercially available drugs. Also, 4-Chloro-7H-pyrrolo[2,3-d] pyrimidine was the intermediate of the bulk drug, Tofatinib, which was widely used in treatment of adult patients with moderate to severe rheumatoid arthritis with inadequate or intolerant methotrexate response. | ||
| M24810 | Eftilagimod alfa | Others |
| IMP321; LAG-3Ig | ||
| Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research. | ||
| M28468 | IMP2-IN-2 | Others |
| IMP2-IN-2 (compound 6) is a potent and selective IMP2 inhibitor, with IC50s of 120.9 μM and 236.7 μM for IMP2 interaction with RNA_A and RNA_B, respectively. IMP2-IN-2 can be used for the research of cancer. | ||
| M28526 | IMP2-IN-1 | Others |
| IMP2-IN-1 (compound 4) is a potent IMP2 inhibitor with IC50 value of 81.3~127.5 for IMP2 RNA sequence. IMP2-IN-1 reduces IMP2 in SW480 cells. IMP2-IN-1 significantly reduces the viability of both differentiated and non-differentiated Huh7 cells. | ||
| M29631 | BC-DXI-843 | Others |
| BC-DXI-843 is a potent and specific AIMP2-DX2 inhibitor with an IC50 of 0.92 μM, more than 100-fold selectivity over AIMP2 (IC50 >100 μM) in a luciferase assay. BC-DXI-843 acts as a promising lead targeting AIMP2-DX2 in lung cancer. | ||
| M29946 | L48H37 | TLR |
| L48H37 is an analog of Curcumin with improved chemical stability. L48H37 is a potent and specific myeloid differentiation protein 2 (MD2) inhibitor and inhibits the interaction and signaling transduction of LPS-TLR4/MD2. L48H37 is used for the research of sepsis or lung injury treatment. | ||
| M54551 | Rademikibart | IL Receptor/Related |
| CBP-201 | ||
| Rademikibart is a human IgG4ҡ monoclonal antibody that targets IL-4 Rα to block inflammatory signaling induced by IL-4 and IL-13, two important cytokines that drive allergic inflammation, and binds to the human IL-4Rα epitope with a KD of 20.7 pM. Rademikibart does not bind to IL-4Rα from other species. Rademikibart does not bind to IL-4Rα of other species.Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation, and TARC production in PBMC, and can be used in studies related to moderate-to-severe Th2 inflammatory diseases. | ||
| M58469 | CS-6253 TFA | Others |
| CS-6253 TFA is an agonist for ATP-binding cassette 1 (ABCA 1). CS-6253 TFA improves the amyloid-β42/40 ratio, and affects lipoprotein metabolism in plasma. CS-6253 TFA generates cholesterol-rich high-density lipoprotein (HDL) particles, and induces the release of microparticles. | ||
| M58492 | CS-6253 | Others |
| CS-6253 is an agonist for ATP-binding cassette 1 (ABCA 1). CS-6253 improves the amyloid-β42/40 ratio, and affects lipoprotein metabolism in plasma. CS-6253 generates cholesterol-rich high-density lipoprotein (HDL) particles, and induces the release of microparticles. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
